Cited by 59RNA Research and SplicingCancer-related Molecular PathwaysCancer-related molecular mechanisms research

Alternative splicing of the p53 tumor suppressor gene in the Molt-4 T-lymphoblastic leukemia cell line

Chow, Vincent T.K., Quek, H.H., Tock, Edward P.C.·1993·Cancer Letters

Abstract

The expression of the p53 tumor suppressor gene in ten human cell lines (nine cancers and one normal) was studied using reverse transcription, polymerase chain reaction (PCR) and direct sequencing. Using P53U and P53D primers for amplifying a 371-base pair (bp) target fragment spanning exons 7-10 of p53 cDNA, normal-sized PCR products were amplified from 9 cell lines but not from the Hep3B hepatocellular carcinoma (HCC) cell line. An additional larger band (504 bp) was observed for the Molt-4 T-lymphoblastic leukemia cell line. Employing P531 and P53D primers which flank a 76-bp p53 cDNA fragment, 76 bp as well as 209 bp products were generated by PCR of Molt-4 cDNA. Direct sequencing of the 504 bp and 209 bp bands confirmed the presence of a 133 bp insertion between exons 9 and 10 in the aberrant transcript. This insertion was homologous to a 130-bp sequence within the wild-type p53 intron 9, except for 2 point mutations and 3 base insertions. Sequencing of P53U/P53D PCR products of Molt-4 genomic DNA revealed an 8 bp deletion just downstream to the 133 bp insertion, creating a novel donor splicing site within intron 9. This site, coupled with an inherent acceptor splicing site just upstream to the 133 bp insertion, suggests that the 133 bp stretch represents an alternative exon. The occurrence of a termination signal within this alternative transcript is predicted to culminate in a truncated p53 translational product. The sequences of the 371 bp PCR products of Molt-4, HT-1…

Integrity signals

Registry

Crossref · 10.1016/0304-3835(93)90256-9

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The RAJI cell line harbors the loss-of-function mutant alleles R213Q and Y234H.

    “The cell line RAJI, which harbors the loss-of-function mutant alleles R213Q and Y234H [34–36] for p53 targets including TLR3 and p21 (Supplementary Figure S4A), was treated with the reactivating drugs RITA [36] and PRIMA-1 [37] as well as with the anticancer drugs doxorubicin (DXR) and 5-fluorouracil (5FU) to induce p53.”

Cites

Flagged first, then by citations

9 of the 46 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Chow, V. T. K., Quek, H. H., & Tock, E. P. C.
Affiliations
National University of Singapore (SG)
Corresponding author
Chow, Vincent T.K.
Venue
Cancer Letters
Publisher
Elsevier BV
Published
1993-09
Volume
73
Issue
2-3
Pages
141-148
ISSN
0304-3835 (ISSN-L)
OpenAlex
W2000937841
Cited by
59
References
46
Citations by year
2023: 2 · 2022: 1 · 2017: 1 · 2016: 2 · 2014: 1 · 2012: 2
FWCI
0.90
Type
journal article
Language
en
Open access
closed
Locations
  • Cancer Letters (publishedVersion)
  • PubMed (publishedVersion)
  • National University of Singapore (submittedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Research and Splicing
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
Keywords
p53, alternative splicing, MOLT-4 cells, T-cell acute lymphoblastic leukemia, alternative exons, TP53 mutation, hepatocellular carcinoma, Burkitt lymphoma, tumor suppressor gene expression
MeSH terms
Amino Acid Sequence, Base Sequence, DNA, Neoplasm, Humans, Molecular Sequence Data, Transcription, Genetic, Tumor Cells, Cultured, Leukemia-Lymphoma, Adult T-Cell, Gene Expression, Polymerase Chain Reaction, Genes, p53, Alternative Splicing, Sequence Analysis, DNA

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review